Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Ultragenyx Pharmaceutical Inc    RARE

ULTRAGENYX PHARMACEUTICAL INC (RARE)
My previous session
Most popular
  Report  
Delayed Quote. Delayed  - 12/14 10:00:04 pm
46.01 USD   -2.75%
2014Amid Alibaba fever, reasons for caution in IPO market
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

FDA, EMA to review Novartis' siponimod for secondary progressive MS

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/09/2018 | 10:27am CET

Novartis AG (NYSE:NVS; SIX:NOVN) said FDA and MAA have accepted applications for siponimod (BAF312) to treat secondary progressive multiple sclerosis (SPMS). The PDUFA date for the NDA is in March 2019; Novartis expects a decision from EMA in late 2019.

The pharma used a Priority Review voucher to speed siponimod's review. Novartis spokesperson Eric Althoff said the company used the voucher it purchased from Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) in 2017; Novartis paid $130 million for the voucher (see "Novartis Buying Ultragenyx's Priority Review Voucher").

The applications are supported by data from the Phase III EXPAND trial which showed that siponimod reduced the risk of six-month confirmed disability progression by 26% compared with placebo (20% vs. 26%, HR=0.74, 95% CI: 0.6, 0.92, p=0.0058) in SPMS patients (see "Novartis Planning Submissions for Secondary Progressive MS Candidate").

Siponimod is a second-generation sphingosine 1-phosphate receptor 1 (S1PR1; S1P1; EDG1) agonist. It was designed to avoid some of the cardiovascular side effects seen with Novartis' MS drug Gilenya fingolimod, a first-generation S1P receptor agonist (see "Devil Is in the Dosing").

Celgene Corp. (NASDAQ:CELG) is developing ozanimod (RPC1063), a selective S1PR1 and S1PR5 modulator. In February, FDA issued a refusal to file letter for ozanimod in relapsing MS (see "Rocky Road").

In July, Celgene said it expects to submit in 1Q19 regulatory applications in the U.S. and EU for ozanimod.

.

(C) 2018 M2 COMMUNICATIONS, source M2 PressWIRE

Stocks mentioned in the article
ChangeLast1st jan.
CELGENE CORPORATION -2.21% 68.2 Delayed Quote.-34.65%
NOVARTIS -0.57% 87.02 Delayed Quote.5.61%
ULTRAGENYX PHARMACEUTICAL INC -2.75% 46.01 Delayed Quote.-0.80%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ULTRAGENYX PHARMACEUTICAL
12/07Ultragenyx and Kyowa Kirin Announce Health Canada Approval of Crysvita (buros..
AQ
12/06Ultragenyx and Kyowa Kirin Announce Health Canada Approval of Crysvita™..
GL
11/15ULTRAGENYX PHARMACEUTICAL : Announces Intent to Submit New Drug Application to U..
AQ
11/14ULTRAGENYX PHARMACEUTICAL INC. : Other Events, Financial Statements and Exhibits..
AQ
11/14ULTRAGENYX PHARMACEUTICAL : Announces Intent to Submit New Drug Application to U..
AQ
11/12ULTRAGENYX PHARMACEUTICAL : to Present at Upcoming Investor Conferences
AQ
11/09ULTRAGENYX PHARMACEUTICAL : to Present at Upcoming Investor Conferences
AQ
11/06ULTRAGENYX PHARMACEUTICAL : Management's Discussion and Analysis of Financial Co..
AQ
11/05ULTRAGENYX PHARMACEUTICAL INC. : Results of Operations and Financial Condition, ..
AQ
11/05ULTRAGENYX : 3Q Earnings Snapshot
AQ
More news
Financials ($)
Sales 2018 49,7 M
EBIT 2018 -376 M
Net income 2018 -202 M
Finance 2018 285 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 41,1x
EV / Sales 2019 20,4x
Capitalization 2 327 M
Chart ULTRAGENYX PHARMACEUTICAL INC
Duration : Period :
Ultragenyx Pharmaceutical Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ULTRAGENYX PHARMACEUTICAL
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 70,5 $
Spread / Average Target 53%
EPS Revisions
Managers
NameTitle
Emil D. Kakkis President, Chief Executive Officer & Director
Daniel G. Welch Non-Executive Chairman
Wladimir Hogenhuis Chief Operating Officer
Shalini Sharp Chief Financial Officer & Executive Vice President
Dennis Karl Huang Chief Technical Operations Officer & Senior VP
Sector and Competitors
1st jan.Capitalization (M$)
ULTRAGENYX PHARMACEUTICAL INC-0.80%2 327
GILEAD SCIENCES-8.47%84 823
VERTEX PHARMACEUTICALS15.72%43 460
REGENERON PHARMACEUTICALS1.39%40 527
GENMAB3.84%9 952
SAREPTA THERAPEUTICS INC114.81%7 987